Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242379 (
lung cancer
)
71,905
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A new human cancer cell line was established from a metastatic lesion of a small cell lung carcinoma (SCLC-R1) and maintained in continuous culture with a doubling time of 62 h. The SCLC-R1 line, whose ultrastructural features are presented, showed a diploid DNA content, a translocation involving chromosome 16 [t(16;?)(q24;?)] and noticeable deletions in the FHIT (fragile histidine triad) region in the short arm of chromosome 3 [del(3)(p14)] and in the telomeric region of the short arm of chromosome 12 [del(12)(p13)]. The involvement of 12p in metastatic small cell lung cancer is reported here for the first time. No amplification or rearrangements were evident in the c-myc,
L-myc
, N-myc, int-2, c-erbB-2, H-ras, K-ras, c-mos, and hst-1 genes by Southern blot analysis. Wild-type p53, RB, K-ras and H-ras genes were evident by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. The neuron specific enolase (NSE) level was much higher in the cell line's cytosol than in the patient's serum and the cell line also had high expression of chromogranin A and cytokeratin 19. SCLC-R1 cells were sensitive to cisplatin, carboplatin and doxorubicin. The clinical history of the patient from whom the cell line was derived is reported. The characteristics of this new cell line indicate it to be a useful experimental model to investigate
lung cancer
biology and anticancer drug response.
...
PMID:Chromosomal alterations, biological features and in vitro chemosensitivity of SCLC-R1, a new cell line from human metastatic small cell lung carcinoma. 971 81
Specific genetic alterations affecting proto-oncogenes of the myc gene family are frequently detected in human
lung cancer
. Among 11 SCLC cell lines with
L-myc
gene amplification, four were found to have alteration of the RLF gene by Southern blot and RT-PCR analyses. One cell line, NCI-H378, contained aberrantly-sized
L-myc
-hybridizing bands by Southern and Northern blot hybridization but had no alteration of RLF. Some
L-myc
-hybridizing cDNAs from NCI-H378 contained a novel sequence with close homology to the cyclophilins joined to antisense
L-myc
exon 2 sequence. Full length cDNAs isolated from human skeletal muscle containing only the novel sequence identify open reading frames of 301 and 296 amino acids and differ in the C-terminal region by 22 and 17 amino acids. This gene, tentatively named PPIE (peptidyl-prolyl cis-trans isomerase E), has 83% amino acid identity with the central conserved region of cyclophilin A, is evolutionarily conserved by Southern blot, and exhibits differential tissue expression with highest levels found in muscle and brain. Co-amplification of PPIE was observed in seven of eleven
L-myc
amplified cell lines. Analysis of radiation hybrids suggests that the gene order is RLF-PPIE-
L-myc
on chromosome 1p and pulse-field gel electrophoresis localizes all three genes to an 800 megabase Mlu I fragment. The prognostic and functional consequences of PPIE gene amplification in SCLC can now be determined.
...
PMID:Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. 974 81
Human
lung cancer
cells, including small cell lung carcinoma (SCLC), frequently lose expression of retinoic acid receptor beta (RAR-beta) and are resistant to the growth inhibitory activity of all-trans retinoic acid (RA). To elucidate the role of RAR-beta in the growth regulation of SCLC by retinoids, we restored RAR-beta expression in RAR-beta-negative H209 SCLC cells by retroviral transduction (H209-RAR-beta). We found that H209-RAR-beta, but not parental H209 cells, underwent growth inhibition upon RA treatment. RA-treated H209-RAR-beta cells arrested in G1 and displayed reduced
L-myc
expression and cyclin-dependent kinase 2 (cdk2) activity compared with untreated cells. RA treatment of H209-RAR-beta cells was also accompanied by increased expression of the cdk inhibitor p27Kip1, whereas no differences in the expression of
L-myc
or p27Kip1 were detected upon RA treatment of parental H209 cells. The RA-induced growth arrest of H82 SCLC cells, which express endogenous RAR-beta, was also associated with reduced c-myc and increased p27Kip1 expression. We found that ectopic expression of p27Kip1 induced growth inhibition in both H209 and H82 cells, and that sustained myc expression in H209-RAR-beta cells promoted the induction of apoptosis upon RA addition. Our observations indicate that RAR-beta gene transfer can restore RA sensitivity in SCLC cells and suggest that myc and p27Kip1 may represent critical mediators of the RA-induced cell cycle arrest in SCLC cells expressing RAR-beta.
...
PMID:Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression. 1007 29
L-myc
polymorphism was investigated in 95 breast cancer (BC), 63 colorectal cancer (CC) and 58
lung cancer
(LC) patients, as well as in 122 healthy, middle-aged blood donors (HBDs) and 184 elderly, tumor-free individuals. The occurrence of the S allele in the BC cohort (57%) was significantly higher than that in middle-aged, healthy females (41%) and elderly, non-affected women (47%), implying involvement of the
L-myc
genotype in BC susceptibility (age-adjusted OR = 1.74, 95% CI 1.11-2.73, p = 0.016).
L-myc
allele distribution in CC and LC was similar to that in controls. Contrary to earlier reports, L:S allele frequencies ratio in elderly blood donors (EBDs) did not significantly differ from that in HBDs (0.49:0. 51 and 0.54:0.46, respectively). However, the S allele had a tendency to be over-represented among elderly compared with middle-aged smokers (55% vs. 44%; OR = 1.57, 95% CI 0.98-2.50, p = 0. 059), which implies that it may be linked with tolerance to smoking effects.
...
PMID:L-myc polymorphism in cancer patients, healthy blood donors and elderly, tumor-free individuals in Russia. 1070 89
L-myc
S-allele was reported to be associated with metastasis of
lung cancer
, indicating the existence of a putative tumor suppressor gene around the
L-myc
locus, in linkage disequilibrium. The relationship between the S-allele and inactivation of some tumor suppressor gene should be indicated by allelic loss. Therefore, we examined the association between the
L-myc
S-allele and loss of heterozygosity at 11 loci around the
L-myc
locus (1p34.3) in primary lesions or other biological characteristics in
lung cancer
. No associations between the S-allele and allelic loss around the
L-myc
locus or other characteristics were found. According to the deletion map, three shortest regions of overlap between D1S230 and D1S76 were identified. While loss of heterozygosity at SRO1, between D1S2797 and MYCL1, showed no relationship with the pathological stage, it was more frequently observed in squamous cell carcinoma than adenocarcinoma (P=0.019), and associated with high telomerase activity (P=0.046), an indicator of cellular immortality. In conclusion, we found three shortest regions of overlap (SROs) from D1S2797 to pter, and a tumor suppressor gene, which might be associated with suppression of
lung cancer
development but not with
L-myc
S-allele, may exist in SRO1.
Lung Cancer
2000 May
PMID:Allelotype and loss of heterozygosity around the L-myc gene locus in primary lung cancers. 1071 29
We have shown that
L-myc
genotype is associated with the risk of esophageal cancer from smoking and heavy drinking. In this study, we have analyzed the relationship between the
L-myc
genotypes and
lung cancer
risk from smoking in 191 Japanese lung-cancer patients and 241 non-cancer controls. The odds ratios (ORs) were markedly higher in SS and LS genotypes than in LL genotype; age-sex-adjusted ORs were 3.19, 2.30 and 0.92, respectively. This result suggests that the
L-myc
polymorphism may affect the induction of
lung cancer
by smoking. The OR for smoking in SS-genotype patients diagnosed within 2 years was higher than that in other SS patients, suggesting that smoking-related
lung cancer
in SS genotype might exhibit a poorer prognosis.
...
PMID:L-myc genotype is associated with different susceptibility to lung cancer in smokers. 1180 1
It is still controversial whether restriction fragment length polymorphism (RFLP) of the
L-myc
proto-oncogene is correlated with the prognosis in
lung cancer
patients or not. On the other hand, we have shown that the histological pattern of invasion is correlated with the prognosis of surgically treated patients of lung adenocarcinoma. In this study, the
L-myc
RFLP was compared with the histological pattern of invasion and the prognosis in 63 Japanese lung adenocarcinoma patients to evaluate the
L-myc
RFLP as a prognostic marker. Although the histological pattern of invasion was correlated with the prognosis, no correlation was observed between the
L-myc
RFLP and the prognosis. No association was found between the
L-myc
RFLP and the histological pattern of invasion in this study. Our results showed that the
L-myc
RFLP is not a strong prognostic marker compared with histologic pattern of invasion in lung adenocarcinoma.
...
PMID:L-myc restriction fragment length polymorphism and histological pattern of invasion in lung adenocarcinoma. 1183 5
The association of
L-myc
polymorphism with cancer susceptibility and prognosis has produced conflicting results. This may have been due to racial/ethnic differences and methodological variations in the studies, such as, control selection and case stratification. Therefore, we investigated the genotype distribution of the
L-myc
polymorphism in 169
lung cancer
patients and 169 non-cancer controls, and analyzed the association of this polymorphism with cancer susceptibility and prognosis in relation to age-specific controls as well as stratified cases. The genotype frequencies in the Taiwanese non-cancer controls were 0.56 (L) and 0.44 (S). Chi-square (chi(2)) analysis indicated a significant difference in the Taiwanese genotype distribution of
L-myc
compared with that of African-Americans (P=0.001). Logistic regression analysis of cases/controls, adjusted for both age and sex, indicated that an increased frequency of the LL genotype was observed in early-staged patients compared with the non-cancer controls (OR=0.43, 95% CI, 0.20-0.94, P=0.03). In addition, the frequency of the LL genotype was significantly higher in stages I+II patients (47.4%) than in stages III+IV patients (28.4%) (P=0.05). Furthermore, the S allele frequency was significantly increased in stages III+IV patients (P=0.005). As both
L-myc
and p53 polymorphisms were analyzed for their prognostic value, the patients with an S allele of the
L-myc
gene and a Pro/Pro variant genotype of the p53 gene had significantly poorer prognoses compared with other patients (P=0.004, by the log rank test). These data suggest that the S allele of the
L-myc
polymorphism may be associated with
lung cancer
progression.
Lung Cancer
2002 May
PMID:Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. 1195 46
A potential molecular marker associated with cancer susceptibility as well as metastasis, prognosis and adverse survival, is the
L-myc
gene. The studies of
lung cancer
patients from different populations have yielded controversial results. We studied 64 nonsmall cell lung cancer (NSCLC) patients and 37 healthy controls of Turkish origin for
L-myc
gene polymorphism. Our aim was to test the hypothesis that there was association between
L-myc
S allele in NSCLC and predisposition to the disease and TNM stage indicating tumor size, node classification and metastasis. Polymerase chain reaction restriction fragment length polymorphism and agarose gel electrophoresis were used to determine the
L-myc
oncogene genotypes. We found no significant difference, both in the distribution of the LL, LS and SS genotypes and in the allelic frequencies, between the patient group and the control group; that is, the frequencies of
L-myc
alleles were, L and S, 0.59 and 0.41, 0.60 and 0.40, respectively. Our data between the patient group and the control group; that is, the frequencies of
L-myc
alleles were, L and S, 0.59 and 0.41, 0.60 and 0.40, respectively. Our data concerning age, sex, size of tumors, histological type of tumors showed no significant association with
L-myc
genotype. However, a higher frequency of
L-myc
S allele in the squamous cell carcinoma compared to other histological groups was found, although this difference was not statistically significant. No association was found between the
L-myc
RFLP and increased risk of metastasis either to the lymph nodes or to other organs. Our results suggested that
L-myc
gene polymorphism was not a suitable prognostic marker of metastatic development in Turkish NSCLC patients.
...
PMID:Is there any correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human nonsmall cell lung cancer? 1203 23
The non-coding variation in the second intron of the
L-myc
gene, generating an EcoRI polymorphism, is associated with
lung cancer
risk and prognosis. We carried out sequence analysis of the
L-myc
gene in lung adenocarcinoma (ADCA) patients to identify functional polymorphisms and identified a new single nucleotide polymorphism (SNP) in the third exon of the gene causing a Ser362Thr conservative amino acid change in the C-terminus of the encoded protein. This polymorphism showed significant linkage disequilibrium with the
L-myc
EcoRI polymorphism located at 1751 bp distance. Genotyping of the Ser362Thr SNP in 220 Italian ADCA patients and in 230 general population controls revealed a similar low frequency (0.10-0.11) of the Thr allele in both groups. The multivariate odds ratio was 0.68 (95% confidence interval (CI) 0.38-1.22). In the ADCA patients, no significant association between the Ser/Thr polymorphism and survival was observed. Thus, the present results do not support candidacy of the
L-myc
Ser362Thr polymorphism for the functional polymorphism of the
L-myc
genomic region.
...
PMID:A new polymorphism (Ser362Thr) of the L-myc gene is not associated with lung adenocarcinoma risk and prognosis. 1507 94
<< Previous
1
2
3
4
5
6
Next >>